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Resistin promotes the abnormal 
Type I collagen phenotype of 
subchondral bone in obese patients 
with end stage hip osteoarthritis
Ashleigh M. Philp  1, Rebecca L. Collier1, Liam M. Grover2, Edward T. Davis3 & Simon W. 
Jones1
The purpose of this study was to determine the effect of adiposity on the architecture and composition 
of hip OA subchondral bone, and to examine the pathological role of adipokines. Femoral heads were 
collected from normal-weight or over-weight/obese patients with hip OA. Structural parameters of 
subchondral bone were determined by MicroCT and type I collagen α1/α2 ratio was determined by 
SDS PAGE and by qRT-PCR in ex-vivo bone explants. The serum concentration of adipokines was 
determined by Luminex. The effect of resistin on primary OA osteoblasts was determined by analysis 
of Wnt pathway signal transduction, bone nodule formation, and osteoblast metabolic activity. 
Subchondral bone from over-weight/obese hip OA patients exhibited reduced trabecular thickness, 
increased bone surface/bone volume ratio, and an increase in the Type I collagen α1/α2, compared to 
normal-weight hip OA patients. The serum concentration of resistin was higher in overweight/obese OA 
patients, compared to normal-weight OA patients. Stimulation of normal-weight bone explant with 
recombinant resistin increased the Type I collagen α1/α2 ratio. Stimulation of primary OA osteoblasts 
with recombinant resistin increased Wnt signalling activation, osteoblast metabolic activity, and bone 
nodule formation. Increased adiposity in hip OA patients is associated with altered subchondral bone 
architecture and type I collagen composition.
Osteoarthritis (OA) is the most common degenerative joint disease in the world and is typically characterised 
by the loss of articular cartilage and narrowing of the joint space1, 2. Historically, OA has been considered to be a 
disease solely of cartilage degeneration, which has resulted in cartilage being the prime focus of drug discovery 
research3. However, OA is now considered to be a disorder affecting all the tissues within the joint, including the 
subchondral bone. Indeed, evidence has emerged that pathologies identified in OA subchondral bone precede, 
and may contribute to, cartilage degeneration4–6.
For many years, increased adiposity has been recognised as a significant risk factor of OA. A study analysing 
the National Health and Nutrition Examination Survey (NHANES I) concluded that obese females were nearly 
four times more likely to experience OA symptoms than non-obese females, and male obese individuals were 
nearly five times more likely to develop OA symptoms than their normal- weight counterparts7. The increased 
prevalence of OA in both weight-bearing and non-weight bearing joints of obese individuals has led to the emer-
gence of adipose-secreted cytokines8, termed adipokines, as candidate drivers of OA pathology. Adipokines have 
been purported to be key mediators of metabolic health9–11, being associated with metabolic syndrome related 
disorders12, and therefore provide a potential metabolic link between obesity and OA pathology.
To date, research into understanding the role of adipokines in OA joint pathology has predominantly focussed 
on the cartilage tissue by determining the effect of adipokines on chondrocyte phenotype. For example, using iso-
lated primary human chondrocytes, Hui et al.13 discovered that leptin alone, and in synergy with IL-1β, induced 
the expression of catabolic factors metalloproteinases (MMP)-1 and MMP-13 with activation of p38, Erk, PI3K 
and Akt pathways. Leptin has also been demonstrated to increase the production of inflammatory mediators 
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including IL-1β, IL-6, IL-8 and prostaglandin E214. However, cartilage tissue is avascular and thus is unlikely to 
be directly affected by systemic increases in pathological levels of adipokines.
In contrast, subchondral bone is a highly vascularised tissue, and thus would be expected to be influenced by 
differential concentrations of circulatory adipokines reported in over-weight and obese individuals9, 15, 16. Despite 
this, comparative studies of subchondral bone pathology between OA patients of different adiposity has not been 
reported. Furthermore, very little is currently understood regarding the functional role of adipokines in mediat-
ing human OA bone pathology or their effect on the phenotype of human OA osteoblasts. We previously reported 
that there is a temporal relationship between serum levels of adipokines and biomarkers of bone remodelling 
in females with knee OA17, and more recent studies have found that the adipokines visfatin, resistin, and leptin 
modulate osteoblast proliferation and differentiation18–20, supporting the concept that adipokines and increased 
adiposity may impact on OA bone pathology.
Importantly, OA subchondral bone has been referred to as “sclerotic”, with reports of irregular trabecular 
architecture21, abnormal Type I collagen composition22, and dysregulated mineralisation23. Therefore, the aim of 
this study was two-fold. Firstly, to determine whether the trabecular structure and Type I collagen composition 
of subchondral bone differs between normal-weight hip OA patients and overweight/obese hip OA patients. 
Secondly to examine the effect of candidate pathological adipokines on the Type I Collagen composition of 
human hip OA bone and on the phenotype of primary human hip OA osteoblasts.
Results
Greater adiposity in patients with hip OA is associated with an abnormal Type I Collagen com-
position and altered structural parameters in the subchondral bone. Sclerotic subchondral bone 
in patients with knee OA has previously been attributed to an increase in the production of Type I collagen homo-
trimer, due to an increase in the relative proportion of α1 to α2 Type I collagen isoforms22. Therefore, we first used 
SDS PAGE to determine whether the relative proportion of α1 and α2 isoforms differed between subchondral 
bone samples from hip OA patients who were normal-weight (NW) compared to those who were over-weight/
obese (OW/OB). Of significance we found that OW/OB subchondral bone samples exhibited a greater ratio of α1 
to α2 (P < 0.05), compared to NW subchondral bone samples (Fig. 1A).
Next, we performed micro-CT analysis to determine the gross structural parameters of subchondral bone 
samples from the most medial aspect of the femoral head, as depicted in Fig. 1B. Comparing bone from OW/OB 
patients with NW patients, we found no significant difference in either the number (Tb.N) or the spacing (Tb.
Sp) of trabecular. Furthermore, there was no difference in either the structural model index (SMI), degree of 
anistrophy (DA) or ellipsoid factor (EF), suggesting there were no rod or plate-like geometrical differences in the 
trabecular structure between subchondral bone samples from hip OA patients of varying BMI (Table 1). However, 
OW/OB bone exhibited significantly lower Trabecular thickness (TbTh.) compared with NW bone (0.29 ± −0.02 
vs 0.34 ± 0.03 mm), and a significantly higher bone surface/bone volume ratio (7.53 ± 1.14 vs 5.9 ± 0.5 1/mm) 
(Table 1).
The Type I collagen composition of normal-weight hip OA subchondral bone is pathologically 
altered by the adipokine resistin. Following identification of differential collagen formation in the 
subchondral bone from OW/OB hip OA patients, we next examined whether adipokines could provide a systemic 
link to altering bone pathology. To this end, we profiled the circulatory concentrations of 21 known adipokines 
and inflammatory cytokines (namely IL-10, IL-1β, DKK1, MIP-1 α, Chemerin, Eotaxin, gp130, IP10, MCP1, 
Figure 1. Comparison of the structural composition of femoral head subchondral bone in patients of different 
BMI cohorts. (A) The quantification of the α1/α2 Type I collagen ratio in femoral head subchondral bone. 
NW = normal-weight (n = 7), OW/OB = overweight/obese (n = 13). Bars represent mean α1/α2 values ± SEM 
as determined through ImageJ. The gel image is a representative coomassie-stained SDS PAGE gel of a NW 
OA and OW/OB OA femoral head, demonstrating the separation of α1/α2 type I collagen isoforms. (B) 
Representation of the area from the trabecular bone for micro-CT analysis. The area analysed was a 1 cm3 from 
the most medial aspect of the femoral head (as indicated by the red square on the femoral head). Dashed line 
box = region of interest which was reconstructed for bone parameter analysis.
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IL-7, MIP-3 α, amphiregulin, IL-15, aggrecan, resistin, adiponectin, IL-6, LIF, leptin, visfatin and MIP-1β) in 
serum samples collected pre-operatively from NW (n = 38) and OW/OB (n = 112) patients with OA undergoing 
joint replacement surgery (Table 2). Of the adipokines profiled, we identified significant increases in the serum 
concentration of leptin and resistin in the OW/OB patients, compared to the NW patients (Fig. 2A).
We then examined whether chronic stimulation of NW OA subchondral bone tissue with either leptin, resis-
tin or visfatin could pathologically alter the composition of Type I collagen to resemble an OW/OB bone pheno-
type. Bone samples were cultured for 4 weeks in either media containing recombinant leptin (100 ng/ml), resistin 
(500 ng/ml) or visfatin (500 ng/ml) or in culture media alone (control). After 4 weeks, bone tissue was digested 
and Type I collagen composition determined by quantifying the relative expression of α1 and α2 using SDS 
PAGE. Stimulation of NW bone tissue with either leptin or visfatin had no significant effect on the Type I collagen 
α1/α2 ratio. However, NW human bone explants stimulated with resistin exhibited a significant 2.4 fold increase 
in the Type I collagen α1/α2 ratio, compared to bone cultured in control media (Fig. 2B, p < 0.01). This effect was 
further confirmed by a 2.2 fold increase in COL1A1 gene expression following a 24 h resistin stimulation, with 
little increase in COL1A2 gene expression (1.5 fold) (Fig. 2B).
Resistin induces activation of the canonical Wnt signalling pathway in primary osteoblasts iso-
lated from hip OA patients and induces the metabolic activity and bone nodule formation in 
primary osteoblasts isolated from hip OA patients. Mouse models and several genome wide associ-
ation studies have implicated canonical Wnt signalling in mediating bone homeostasis24–26. Therefore, we next 
examined the effect of resistin on the Wnt pathway in primary human hip OA osteoblasts cultured from femo-
ral head bone chips. Firstly, we determined the effect of 24 h resistin stimulation on the expression of 84 genes 
related to Wnt-mediated signal transduction by qRTPCR. Of the 84 genes analysed, 14 genes were found to be 
significantly modulated by >1.4-fold by stimulation with resistin (Fig. 3A). Next, we performed pathway anal-
ysis of these differentially expressed genes using Ingenuity Pathway Analysis software in order to determine the 
predicted activation status of the Wnt pathway signal transducer, β-catenin. Core functional analysis predicted 
an increase in activity and expression of β-catenin (Fig. 3B). To confirm this, we then conducted histochemical 
analyses of β-catenin localisation in primary osteoblasts. Stimulation of osteoblasts for 30 min with recombi-
nant resistin induced nuclear translocation of β-catenin, as demonstrated by an increase in nuclear staining of 
β-catenin in resistin stimulated osteoblasts, compared to non-stimulated media control osteoblasts (Fig. 3C and 
D).
Parameter NW OW/OB p value
Gender (M:F) 3:3 3:3 —
Age (yr) 59 ± 10 57 ± 9 0.749
BMI 23.5 ± 1.1 33.5 ± 2.5 0.007
W:H ratio 0.87 ± 0.07 0.91 ± 0.08 0.303
Body Fat % 23.9 ± 7.3 38.1 ± 7.5 0.008
BV/TV 0.42 ± 0.04 0.43 ± 0.12 0.85
Tb.Th 0.34 ± 0.03 0.27 ± 0.04 0.01
Tb.N 1.25 ± 0.12 1.66 ± 0.62 0.14
Tb.Sp 0.47 ± 0.08 0.41 ± 0.25 0.61
BS/BV 5.91 ± 0.54 7.53 ± 1.14 0.01
SMI −0.27 ± 0.5 −0.4 ± 0.95 0.76
DA 1.55 ± 0.1 1.45 ± 0.2 0.31
EF −0.40 ± 0.14 −0.43 ± 0.22 0.16
Table 1. Micro-CT analysis of OA femoral head subchondral bone samples from Normal-weight (NW, 
n = 6) and over-weight/obese (OW/OB, n = 6) patient cohorts. Patient samples were excluded if a bone 
cyst was present within the 1 cm3 section of femoral head scanned. BV/TV = Bone volume/Total volume; 
TB.Th = Trabecular thickness; TB.N = trabecular number; TB.Sp. = trabecular separation; BS/BV = Bone 
surface/Bone volume; SMI = Structure Model Index; DA = Degree of Anistrophy, EF = Ellipsoid factor. Data 
expressed as mean ± SD.
Parameter NW OW/OB p value
Gender (M:F) 16:22 60:52 —
Age (yr) 67 ± 9 68 ± 8 0.385
BMI 23.2 ± 1.1 31.5 ± 5.1 0.0001
W:H ratio 0.87 ± 0.08 0.93 ± 0.08 0.005
Body Fat % 24.6 ± 10.1 34.8 ± 9.2 0.0001
Table 2. Patient characteristics of normal-weight (NW, n = 38) and over-weight/obese (OW/OB, n = 112) OA 
patient cohorts. W:H ratio = waist circumference:hip circumference. Values represent the mean ± SD.
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It is widely accepted that β-catenin activation is associated with osteoblastic differentiation27. Therefore, we 
next examined whether resistin affected the metabolic activity of primary human OA osteoblasts and their innate 
ability to form mineralised bone nodules.
Primary human hip OA osteoblasts were cultured in either media containing resistin (500 ng/ml), or media 
alone for up to 28 days. After 14 days of culture, alkaline phosphatase activity was measured and was found to be 
significantly higher in osteoblasts stimulated with resistin, compared to control osteoblasts cultured with media 
alone (1.78 ± 0.37 vs. 0.37 ± 0.12 Units/gram; Fig. 4A), suggesting an increase in osteoblast metabolic activity. 
This was confirmed by our finding that stimulation of osteoblasts with resistin increased their basal oxygen con-
sumption rate (OCR) (Fig. 4B).
Finally, we examined whether this resistin-induced greater metabolic phenotype affected the ability of oste-
oblasts to form bone by using Alizarin Red to stain and quantify mineralised nodules. Osteoblasts stimulated 
with resistin for 4 weeks showed greater bone nodule formation (Fig. 4C), compared to osteoblasts cultured with 
media alone. Of note, we found no effect of resistin on the proliferation of osteoblasts (Fig. 4D).
Discussion
This is the first study to examine the relationship between adiposity and subchondral bone structural composition 
in patients with hip OA, and to demonstrate that resistin promotes an abnormal Type I collagen phenotype and 
alters the metabolic and functional activity of primary hip OA osteoblasts.
Collagen structure and alignment is pivotal to the structural integrity of bone22, 28. Therefore, increased pro-
portion of type I collagen homotrimer in OA bone has negative mechanical consequences22. In 2002, Bailey et al. 
demonstrated an increase in the relative proportion of α1 to α2 Type I collagen isoforms in OA subchondral bone 
when compared to fracture neck of femur patients, resulting in poorly organised collagen matrix, reduced miner-
alisation of the bone, and increased lysine hydroxylation22. The α2 chain is thought to be integral to maintaining 
Figure 2. Resistin pathologically alters normal-weight OA bone collagen composition. (A) Serum adipokine 
protein expression in NW (n = 38) and OW/OB (n = 112) patients with OA as determined by Luminex analysis.
Values in table represent mean pg/ml ± stdev. Bars in graph represent mean ± SEM. ***p < 0.0001, *p < 0.05. 
(B) The type I collagen α/α 2 ratio in femoral head subchondral bone explants from NW OA patients following 
stimulation for 4 weeks with either resistin (500 ng/ml), leptin (100 ng/ml), visfatin (500 ng/ml) or media 
control. Bars represent mean ± SEM (n = 4). The ratio of α1/α2 isoforms was quantified by SDS PAGE analysis. 
Gel image is a representative coomassie-stained gel of subchondral bone explants after 4 weeks of adipokine 
stimulation. (B) The mRNA expression of COL1A1 and COL1A2 following acute (24 h) stimulation of primary 
hip OA osteoblasts with either resistin (500 ng/ml) or media control. Expression was determined by Sybr Green 
qRT-PCR, normalised to ACTB. Bars represent mean ± SEM (n = 4).
www.nature.com/scientificreports/
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the triple helix structure of collagen29, increasing the interaction of the hydrophobic side chains and thus limiting 
water content, and allowing for greater cross-linking of the collagen molecules30.
In this paper, we found that the α1/α2 type I collagen ratio was greater in overweight/obese patients with hip 
OA, compared to hip OA patients of normal-weight. This suggests that adiposity may be a primary driver of col-
lagen malformation, leading to accentuated sclerotic bone development and OA progression22.
Structural abnormalities of bone in relation to adiposity were further confirmed via micro-CT. In particular, 
we have demonstrated a significant increase in BS/BV in the subchondral bone of over-weight and obese hip 
OA patients; an indication of higher rates of bone turnover occurring as a result of greater bone surface area31. 
In addition, in this study we have shown a decrease in the trabecular thickness of the subchondral bone in hip 
OA patients who are over-weight/obese, compared to normal-weight patients. This result was surprising since 
an increase in trabecular thickness has previously been reported in OA subchondral bone, compared to non-OA 
bone32. However, previous studies on subchondral bone trabecular thickness have not compared OA patients of 
different adiposity and have been conducted in patients with knee OA33, which is less susceptible to mechani-
cal stresses than the hip joint34. Importantly, dietary-induced obesity in the mouse has been shown to lead to a 
reduction in femoral head trabecular thickness35. Furthermore, Buckland-Wright36 suggested that in advanced 
OA, the greater deformity of articular surfaces leads to greater absorption of local stresses and thus reduced load 
transmission into deeper sub-articular regions resulting in localised osteoporosis36. The differences in trabecular 
thickness we have observed within our study could be due alterations in hip alignment and force transduction, or 
in reference to Buckland-Wright36, could be due to greater deformity of the articular cartilage due to the excessive 
load-bearing evident in over-weight/obese individuals36.
Given that bone is a highly vascularized tissue, and thus susceptible to pathological levels of circulatory adi-
pokines, our findings on the functional effects of resistin in this study are significant. Resistin, is a dimeric pro-
tein, which is associated with insulin resistance in mice37, 38. It is secreted from both adipocytes and macrophages 
and is abundantly expressed in bone marrow cells39. In rheumatoid arthritis, resistin has been shown to accumu-
late within inflamed joints, and to correlate with the degree of inflammation and the expression of inflammatory 
cytokines including TNF-α, IL-1β and IL-6. Furthermore, resistin has previously been reported to promote the 
proliferation of the murine osteoblast precursor cell line, MC3T3-E119. However, despite these findings, very little 
Figure 3. Analysis of the Wnt signalling pathway in human primary osteoblasts following resistin stimulation. 
(A) Canonical Wnt signalling pathway gene expression following resistin stimulation. Primary human 
osteoblasts cells were stimulated with 500 ng/ml recombinant resistin for 24 hours prior to gene analysis, with 14 
genes shown to be up-regulated (**p < 0.01, *p < 0.05). (B) IPA analysis of Wnt genes differentially expressed 
>1.4 fold change with resistin stimulation and the predicted increase in β-catenin activity and expression. 
Orange arrows = predicted activation, grey arrows = effect not predicted. (C) Representative images of nuclear 
translocation of β-catenin in human osteoblasts following i) media only ii) 30 min of resistin stimulation 
(500 ng/ml). Green = α-Actin, Blue = Hoechst, and Red = β-Catenin (n = 3). (D) Quantification of nuclear 
translocation of β-catenin in human primary osteoblasts using Image J software. Percentage nuclear β-catenin 
refers to the subset within the area of hoechst staining compared to the whole cell and is an average of 6 images 
from 3 OA patient cell lines (n = 3).
www.nature.com/scientificreports/
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is understood with regards to the role of resistin in bone pathology, its effect on primary OA osteoblasts and its 
overall impact on bone remodelling and collagen formation in OA.
In the present study, we found that circulatory levels of both resistin and leptin were significantly elevated in 
over-weight/obese OA patient serum compared to normal-weight patients with OA. The association of leptin and 
resistin with obesity is in support of previous research16, 40–42. However, we have provided evidence that resistin, 
unlike leptin, significantly affects the type I collagen composition of subchondral bone, driving the phenotype of 
normal-weight bone towards a sclerotic homotrimer-rich type I collagen phenotype, consistent with that exhib-
ited by over-weight/obese bone.
Stimulation of primary OA osteoblasts with resistin increased the activation of the canonical Wnt signalling 
pathway, as indicated by the rapid nuclear translocation of β-catenin and the induction of multiple Wnt-mediated 
signal transduction genes. Critically, the Wnt pathway is believed to be a principal pathway in bone remodelling. 
It is a known regulator of both alkaline phosphatase activity and osteoblastic differentiation43, 44. Furthermore, 
mutations in Wnt signalling mediators such as the Wnt receptor LRP5 have been associated with abnormal bone 
mass45, 46. Therefore, the current finding that resistin activates the Wnt pathway in primary OA osteoblasts further 
supports the role of resistin in driving pathological bone formation in obese patients with hip OA.
Further analysis on the role of resistin in bone demonstrated that resistin directly affects the activity and 
function of primary human OA osteoblasts. Similarly to the effect previously reported of resistin on murine 
osteoblast precursors19, we found that resistin increased alkaline phosphatase activity following a 14 day stimu-
lation of osteoblasts. Importantly, dysregulated alkaline phosphatase activity has also been associated with bone 
pathologies47, 48, and greater alkaline phosphatase activity has been reported in osteoblasts from OA bone. Mature 
osteoblasts exhibit higher alkaline phosphatase activity. Therefore, it has been speculated that the elevated alka-
line phosphatase activity in OA osteoblasts could reflect increased differentiation of pre-osteoblasts into mature 
osteoblasts49, 50. This is further supported by the increased metabolic rate we have demonstrated.
Consistent with the resistin-mediated induction of osteoblast metabolic activity, we also observed that chronic 
stimulation with resistin increased osteoblast bone nodule formation. This finding appears counterintuitive to 
previous studies that have shown a negative correlation with serum resistin levels and bone mineral density51, 
52. However, resistin has been shown to increase cytosolic calcium in human hepatic stellate cells53. Importantly, 
in osteoblasts it has been shown that increases in cytosolic calcium can contribute to increased extracellular 
Figure 4. The functional impact of resistin on the metabolic activity and bone nodule formation of human 
primary OA osteoblasts. (A) Alkaline phosphatase activity of human primary OA osteoblasts from the 
femoral subchondral bone following 2wk stimulation with either resistin (500 ng/ml) or media control. Bars 
represent mean values ± SEM (n = 4). (B) The fold change in the oxygen consumption rate (OCR) following 
24 h stimulation of primary human OA osteoblasts with resistin (500 ng/ml), compared to non-stimulated 
osteoblasts. OCR values (pmol/min) were normalized to total protein following cell lysis prior to fold change 
calculation. Bars represent mean values ± SEM (n = 10). (C) Representative image of alizarin red stained 
mineralised bone nodules following 4 wk stimulation of primary hip OA osteoblasts with either resistin 
(500 ng/ml) or media control. Alizarin red staining was quantified using Image J software. Bars represent 
mean values ± SEM (n = 4). (D) Time-course of human primary hip OA osteoblast cell proliferation following 
stimulation with and without resistin (n = 4).
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hydroxyapatite formation54. Therefore, our finding that resistin drives bone nodule formation could be due to 
increases in cytosolic calcium in osteoblasts.
Of note, we observed no effect of resistin on the proliferation of human primary OA osteoblasts. Therefore, 
the positive induction of bone nodule formation in osteoblasts stimulated with resistin appears more likely to 
reflect an effect of resistin on osteoblast maturation and osteoid development. In this context, it was recently 
reported that resistin, as well as the adipokines visfatin and adiponectin are present in knee osteophytes55. Of 
interest, Junker et al. found that adiponectin was found to induce p38 MAPK signalling in primary knee OA oste-
oblasts, suggesting that adipokines may also influence osteophyte development by modulating proinflammatory 
conditions55.
It is important to note that all the joint tissue samples used in this study were obtained peri-operatively from 
hip OA patients undergoing total joint replacement suffering from late-stage disease, where typically there is 
substantial articular cartilage loss. It is inherently difficult to obtain bone tissue from patients with early stage hip 
OA disease. Therefore, our dataset excludes any patients with less severe OA where the femoral head subchondral 
bone would be expected to have greater cartilage coverage.
To conclude, our data has demonstrated that adiposity affects the structural composition of the femoral head 
subchondral bone in patients with hip OA, indicative of an increase in Type I collagen homotrimer content. 
Furthermore, we have shown that the adipokine resistin is elevated in over-weight/obese OA patients, compared 
to normal-weight OA patients and promotes an obese subchondral bone phenotype. The effect of resistin on the 
phenotype of primary human OA osteoblasts, and its activation of canonical Wnt signalling, stresses the impor-
tance of continuing to investigate the role of adipokines in OA pathology, particularly in relation to those patients 
with OA who are over-weight or obese.
Methods
Ethical Approval and Subject Recruitment. All experiments and methods were performed in accord-
ance with relevant guidelines and regulations. All experimental protocols were approved by a named institutional/
licensing committee. Specifically, the University of Birmingham, UK Research Ethics committee granted ethical 
approval (NRES 14-ES-1044), in accordance with the principles of Good Clinical Practice guidelines. Participants 
were recruited on a volunteer basis, after being fully-informed of the study requirements by the clinical research 
staff of collaborating hospitals. Consent was obtained from all patients for study participation and any identify-
ing information removed from images in this publication. Femoral heads were collected at the time of surgery 
from hip OA patients undergoing total hip arthroplasty at The Royal Orthopaedic Hospital, Birmingham (UK) 
or Russell’s Hall Hospital, Dudley (UK). Height and weight measurements were recorded to determine BMI, and 
blood samples were collected pre-operatively from 112 over-weight/obese and 38 normal-weight patients with 
OA. All study participants were aged between 45 and 80 years of age. All participants demonstrating secondary 
causes of OA, such as avascular necrosis, Perthes disease, developmental dysplasia, previous acetabular or femoral 
neck fractures and slipped upper femoral epiphysis, were excluded from the study.
Serum adipokine profiling by Luminex. To determine the circulatory concentration of adipokines, mul-
tiplex technology (Luminex Screening Assay, R and D Systems) was performed according to the manufacturer’s 
instructions. In brief, OA patient serum samples were diluted to 1:2 in assay buffer, and the concentration of 21 
adipokines were quantified using a Luminex 200 instrument (Luminex Corporation, Austin, Texas, USA).
Molecular composition of bone type I collagen. Quantification of Type I Collagen α1/α2 composition 
was performed as previously described by Bailey et al.22. Briefly, 150 mg of powdered bone was washed in PBS 
(Sigma, UK) then resuspended in decalcifying buffer (10% (w/v) EDTA, 30 mM TRIZMA base and 4 M guanidine 
hydrochloride at pH 7.5) and placed on a rotator at 4 °C. Decalcified bone samples were centrifuged at 5000 rpm 
for 10 minutes, with the insoluble fraction resuspended in pepsin solution (0.5 M acetic acid and 0.5% w/w pepsin 
(based upon original bone weight), P6887, Sigma) and rotated at 4 °C for 48 hr. Following pepsin incubation, the 
centrifuged pellet was discarded and pooled supernatants were freeze dried and analysed by gel electrophoresis.
Micro-CT scanning. Bone cubes (1 × 1 × 1 cm) were cut by the Royal Orthopaedic Hospital pathology ser-
vice, from the most medial aspect of the femoral head, as shown in Fig. 1B. Bone cubes were washed in acetone 
and allowed to air dry prior to micro-CT scanning. Gross structural parameters were determined using a Bruker 
Sky scan 1172 (Bruker Skyscan 1172, e2v technologies plc, Chelmsford, UK). Sample resolution size was set 
to 9.87 μm, with an exposure time of 200 ms and a rotation step of 0.4°, and no filter was applied. Scans were 
performed at 49 kV. Approximately 800 scan slices were collected per sample, with 60% beam hardening correc-
tion and a ring artefact correction of 5. Reconstruction was performed using the NRecon software version 1.6.2 
(SkyScan, e2v technologies plc, Chelmsford, UK).
Reconstruction and analysis. Post alignment of each image was minor at 0 ± 1. The reconstruction set-
tings were maintained for all samples (Smoothing = 2, smoothing kernel = 0, reconstruction duration per slice 
0.18 s). One hundred slices immediately below the cortical bone layer (As shown in Fig. 1B) were isolated and 
assayed for quantitative analysis. Regions of interest were drawn within the bone area for each sample. Adaptive 
thresholding was performed (Settings; round kernel, radius 4, constant 0, background dark, pre-threshold on, 
lower grey threshold 69, upper grey threshold 255), and white speckles were removed (<20 voxels). Finally a 
despeckle sweep of the 3D space was used to correct for image irregularities and images were analysed using 
CTVol software (SkyScan, e2v technologies plc, Chelmsford, UK).
Primary osteoblast and ex-vivo bone explant culture. Subchondral bone chips were cut from the 
femoral head using a Friedman Rongeur, and washed three times in DMEM containing 100 U/mL penicillin 
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streptomycin to remove excess fat, blood, marrow, and connective tissue. To isolate primary human osteoblasts, 
small bone chips (<3 mm3) were placed into a 25 cm2 vented flask with osteoblast differentiation media (DMEM, 
10% FBS, 100 Units/mL Penicillin Streptomycin, 2 mM L-Glutamine, 1% NEAA, 2 mM β-glycerophosphate diso-
dium salt hydrate, 50 ug/mL L-Ascorbic Acid, 10 nM Dexamethasone). Bone chips were cultured in a humidified 
atmosphere of 37 °C and 5% CO2 and left for 5 days before the initial media change. Following 5 days, differen-
tiation media was changed every 3 days, and bone chips were removed once primary osteoblast cell coverage 
reached approximately 30% confluency. For osteoblast and ex-vivo bone explant stimulations, recombinant pro-
teins (Resistin, 500 ng/ml; Leptin 100 ng/ml; Visfatin, 500 ng/ml; all from Cambridge Biosciences) were diluted in 
primary osteoblast differentiation media. The selected adipokine concentrations were chosen based on previously 
published studies on adipokine stimulation of cells from the joint. The concentrations used are higher than the 
systemic adipokine concentrations in order to reflect that the absolute quantity of adipokines exposed to osteo-
blasts in vivo will be greater than in osteoblast in vitro studies, due to blood flow through bone tissue56–60.
Gene expression analysis. To determine the effect of resistin on the Wnt signalling pathway, total RNA 
was isolated from human hip OA primary osteoblasts stimulated with or without resistin (500 ng/ml) for 24 h. 
The mRNA expression of 84 genes related to Wnt-mediated signal transduction was determined by qRT-PCR 
using an RT2 Profiler PCR array kit (Qiagen) as per the manufacturer’s instructions. The mRNA expression of 
COL1A1 and COL1A2 was determined by Sybr Green qRT-PCR using primers designed by Dharmacon (GE 
LifeSciences, UK).
Pathway analysis. Pathway analysis was performed using the pathway analysis software application 
Ingenuity Pathway Analysis (IPA; www.ingenuity.com). Using a cut-off filter of ± >1.4 fold change and signif-
icance P < 0.05, genes that were differentially expressed upon resistin stimulation of primary osteoblasts were 
entered into the IPA software to generate a network map. A core functional analysis was then performed in order 
to determine the predicted activation status of the Wnt signal transducer beta-catenin.
Osteoblast bone mineralisation. Human OA osteoblasts were seeded at 6 × 103 cells per well in a 24 
well plate and treated with or without adipokine stimulation as described previously. After 14 days, cells were 
stained with alizarin red solution (0.5% Alizarin Red (Sigma, UK) in 1% ammonia hydroxide at pH 4.5) for 
10 min at room temperature and washed with PBS to remove excess stain. Cells were then incubated in 10% 
cetyl pyridinium chloride (Sigma, UK) for 10 min at room temperature. The supernatant was collected from 
each well and diluted 1:10 with the 10% cetyl pyridinium chloride and read at OD550 nm on a microplate 
Reader (Biotek, Elx808).
Osteoblast alkaline phosphatase activity. Alkaline Phosphatase (ALP) (Human placenta, P3895, 
Sigma) was diluted to 100 Units/mL in 1 mM MgCl2 (P2670, Sigma) and stored at −20 °C. Human osteoblast 
cells were seeded at 6 × 103 cells per well in a 24 well plate and treated with or without adipokine stimulation as 
described previously. Osteoblasts were lysed in RIPA diluent buffer ((0.2x RIPA buffer, 1 mM MgCl2) and diluted 
1:5 with 1 mM MgCl2. Diluted osteoblast lysates were combined with ALP substrate (solution containing pNPP, 
P7998, Sigma) and incubated at 37 °C for 15 min. The reaction was stopped with the addition of 0.1 N NaOH and 
read immediately at 405 nm (Biotek, ELx808).
Osteoblast oxygen consumption analysis. Osteoblasts were seeded at a density of 6 × 103 cells in 
XFe24-well cell culture microplates (Seahorse Bioscience, North Billerica, MA). Prior to the assay, cells were 
placed in 600 μl of Seahorse XF Base Medium (pH 7.4, 10% FBS, 4.6 g/L glucose, 2 mM β-glycerophosphate dis-
odium salt hydrate, 10 mM Dexamethasone) pre-warmed to 37 °C. The plate was then transferred to a non-CO2 
incubator for 1 h. Following calibration, oxygen consumption measurements were performed for basal respira-
tion. Upon completion of the assay, cells were collected in lysis buffer (RIPA buffer; 0.4% protease inhibitor cock-
tail) and centrifuged for 10 min at 8,000 g and the supernatant was removed for protein determination. Protein 
concentration was determined using the BCA protein assay (Pierce, UK).
Osteoblast cell proliferation assay. Proliferation was determined using the CellTiter 96® Aqueous One 
Solution Cell Proliferation Assay kit (Promega, USA), as per the manufacturer’s instructions.
Immunocytochemistry of β-Catenin localisation in primary hip OA osteoblasts. Osteoblasts 
were plated in a 24 well plate for 24 h prior to resistin stimulation (as previously stated). Following stimulation, ice 
cold 4% paraformaldehyde was added to each well for 20 min. Cells were then washed with PBS before incubation 
for 1 h in vehicle (10% goat serum in PBS and 0.1% Triton X-100). Cells were then incubated in vehicle contain-
ing primary antibody α-β-catenin (AB6302, Abcam, UK) α-Actin (AC-40, Sigma, USA) overnight. Following 
primary antibody incubation, cells were washed and incubated in vehicle and secondary antibody (α-Rabbit 
H+L, Alexa Fluor 555, Pierce, UK) for 1 h with the addition of DAPI (4083, CST, USA). Cells were washed before 
mounting with Prolong® Diamond Antifade Moutant (Thermofisher).
Statistical Analysis. Descriptive statistics were tabulated to detail patient characteristics (Mean ± SD). 
Gaussian distribution was confirmed using Kolmogorov-Smirnov test. A one-way ANOVA with Tukey Post-Hoc 
was used to determine collagen homotrimer significance. Unpaired t-tests were performed to determine differ-
ences in serum adipokine concentrations in patients of different BMI categories and to determine the effect of 
recombinant adipokines on osteoblasts in culture, using a confidence of >95% to demonstrate statistical signifi-
cance. To analyse the WNT pathway gene expression all samples were log transformed prior to statistical analysis. 
All statistical calculations were performed using Graphpad Prism software.
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